Combining sorafenib with chemoembolization for hepatocellular cancer
The combination of the small molecule kinase inhibitor sorafenib with transarterial chemoembolization (TACE) may have the potential to improve clinical outcomes in patients with hepatocellular carcinoma (HCC) by blocking the angiogenic signaling activated by the chemoembolization. In this article, the authors offer a glimpse at some preliminary data using this treatment for advanced HCC, which is not yet recommended outside the clinical trial
setting. Over the coming years, efficacy data from ongoing randomized studies will emerge, helping to optimize
and perhaps extend the use of this novel treatment approach in conjunction with other locoregional therapies.
FROM THE FEDERAL REGISTER
ABOUT THE AUTHORS
Affiliations: Dr. Choi is Assistant Professor of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI. Dr. Critchfield is Assistant Professor of Radiology and Chief of Interventional Oncology, Detroit Medical Center, Wayne State University School of Medicine, Detroit, MI. Dr. Philip is Professor of Medicine, Wayne State University School of Medicine, and Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, MI. Conflicts of interest: The authors have no conflicts of interest to disclose.
1 Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, and 2 Department of Radiology, Section of Interventional Radiology, Detroit Medical Center, Wayne State University School of Medicine, Detroit, MI
